Triticum Aestivum
Phase 3Small molecule
Triticum Aestivum is one of 32 small molecule programs targeting Obesity. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1Triticum Aestivum
CCoordinación de Investigación en Salud, Mexico
Phase 3
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Adenocard
AstellasPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Prometrium
FerringPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Obesity2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Triticum Aestivum. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details